Genfit S.A. (OTCMKTS:GNFTF) Short Interest Down 88.1% in December

Genfit S.A. (OTCMKTS:GNFTF) saw a large decline in short interest in December. As of December 31st, there was short interest totalling 500 shares, a decline of 88.1% from the December 15th total of 4,200 shares. Based on an average daily volume of 400 shares, the short-interest ratio is presently 1.3 days.

Genfit Price Performance

OTCMKTS:GNFTF remained flat at $3.54 on Monday. Genfit has a 1 year low of $2.95 and a 1 year high of $5.55. The firm’s fifty day moving average is $4.85 and its 200-day moving average is $4.93.

About Genfit

Genfit SA, a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis.